|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Tumors were classified as high GDF11 expression (n=65) or low GDF11 expression (n=65).
|
17912435 |
2007 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, GDF11 has a tumor suppressor role in liver cancer, exerts its effects through Smad2/3 signaling and may serve as a novel tumor marker in liver cancer diagnosis.
|
29545874 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Intracellular GDF11 retention adds to the concept of tumor-suppressor inactivation and reveals a cell-biological vulnerability for TNBCs lacking therapeutically actionable mutations.
|
29161592 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion.
|
30890427 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings suggested that GDF11 acted as a tumor suppressor gene for pancreatic cancer.
|
30568460 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We also demonstrate that CRC-associated human intestinal lymphatic endothelial cells regulate tumor cell growth via growth differentiation factor 11, a soluble matrisome component which in CRC patients was found to be associated with tumor progression.
|
30889293 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
This review is focused to present and analyze the recent findings in the emerging research field of GDF11 function in cancer and metabolism, and discusses the controversies surrounding the biology of this atypical growth factor.
|
31681577 |
2019 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The latest studies have shown that the level of circulating GDF 11 correlates with the outcomes of patients with cardiovascular diseases, cancer and uremia.
|
28223232 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Administration of GDF11 may be an efficacious therapy to protect against cardiovascular diseases in splenectomized patients.
|
27565745 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
This review is focused to present and analyze the recent findings in the emerging research field of GDF11 function in cancer and metabolism, and discusses the controversies surrounding the biology of this atypical growth factor.
|
31681577 |
2019 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
As such, GDF11 could be considered as an important therapeutic candidate for age-related neurodegenerative and metabolic disorders.
|
31637864 |
2020 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
These results demonstrate that GDF11 plays an important role in regulating metabolic homeostasis and energy balance and could be a target for pharmacological intervention to treat metabolic disease.
|
31847906 |
2019 |
|
Cerebrovascular accident
|
0.020 |
Biomarker
|
group |
BEFREE |
Here we examined effects of GDF11 on angiogenesis and recovery of neurological function in a rat model of stroke.
|
29432795 |
2018 |
|
Cerebrovascular accident
|
0.020 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> GDF11 was upregulated in the ipsilateral peri-infarct cortex and subventricular zone (SVZ) at 14 days after stroke.
|
30061815 |
2018 |
|
MYELODYSPLASTIC SYNDROME
|
0.020 |
Biomarker
|
group |
BEFREE |
In the present study, we show that iron overload impairs the frequency and colony-forming capacity of normal hematopoietic stem and progenitor cells, especially in erythroid, in MDS mice, which is due, at least in part, to growth differentiation factor 11-induced reactive oxygen species, shortening survival of MDS mice.
|
29903757 |
2018 |
|
MYELODYSPLASTIC SYNDROME
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Luspatercept (and sotatercept), ligand traps that particularly inhibit GDF11, lead to RBC transfusion independence in 10% to 50% of lower-risk MDSs resistant to available treatments, and have started to be used in PMF.
|
30602619 |
2019 |
|
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Clinical significance of growth differentiation factor 11 in colorectal cancer.
|
17912435 |
2007 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that GDF11 repletion may enhance EPC resistance to diabetes-induced damage, improve angiogenesis, and thus, increase blood flow.
|
30026260 |
2018 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
GDF11 inhibits proliferation and apoptosis of esophageal cancer cells.
|
30213293 |
2018 |
|
Heart Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GDF11 levels were not related to the presence of hypertension or cardiopathy.
|
31248139 |
2019 |